Intervention Review

You have free access to this content

Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease

  1. Martin Chalumeau1,*,
  2. Yvonne CM Duijvestijn2

Editorial Group: Cochrane Acute Respiratory Infections Group

Published Online: 31 MAY 2013

Assessed as up-to-date: 6 MAR 2013

DOI: 10.1002/14651858.CD003124.pub4


How to Cite

Chalumeau M, Duijvestijn YCM. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD003124. DOI: 10.1002/14651858.CD003124.pub4.

Author Information

  1. 1

    Necker Hospital, AP-HP and Paris Descartes University, INSERM U953 and Department of Pediatrics, Paris, France

  2. 2

    Medical Centre Alkmaar, Department of Paediatrics (119), Alkmaar, Netherlands

*Martin Chalumeau, INSERM U953 and Department of Pediatrics, Necker Hospital, AP-HP and Paris Descartes University, Paris, France. martin.chalumeau@gmail.com. martin.chalumeau@nck.aphp.fr.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions), comment added to review
  2. Published Online: 31 MAY 2013

SEARCH

[Figure 1]
Figure 1. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
[Figure 3]
Figure 3. Forest plot of comparison: 1 Febrile state (AC vs placebo), outcome: 1.1 Febrile state after 6 days.
[Figure 4]
Figure 4. Forest plot of comparison: 4 Cough (AC vs placebo), outcome: 4.1 Cough after 6 to 7 days.
[Figure 5]
Figure 5. Forest plot of comparison: 3 Dyspnoea (AC or CC versus placebo), outcome: 3.1 Dyspnoea after 6 to 7 days.
[Figure 6]
Figure 6. Forest plot of comparison: 3 Thoracic semeiologic alterations (AC vs placebo), outcome: 3.1 Thoracic semeiologic alterations (after 3 days).
[Analysis 1.1]
Analysis 1.1. Comparison 1 Febrile state (AC or CC versus placebo), Outcome 1 Febrile state after 6 days.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Febrile state (AC or CC versus placebo), Outcome 2 Febrile state after 6 days.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Cough (AC or CC versus placebo), Outcome 1 Cough after 6 to 7 days.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Cough (AC or CC versus placebo), Outcome 2 Cough after 6 to 7 days.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Cough (AC or CC versus placebo), Outcome 3 Cough at the end of treatment (= 28 days).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Cough (AC or CC versus placebo), Outcome 4 Cough at the end of treatment (= 28 days).
[Analysis 3.1]
Analysis 3.1. Comparison 3 Dyspnoea (AC or CC versus placebo), Outcome 1 Dyspnoea after 6 to 7 days.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Dyspnoea (AC or CC versus placebo), Outcome 2 Dyspnoea after 6 to 7 days.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Thoracic semeiologic alterations (AC versus placebo), Outcome 1 Thoracic semeiologic alterations after 5 days.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Thoracic semeiologic alterations (AC versus placebo), Outcome 2 Thoracic semeiologic alterations after 5 days.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Thoracic semeiologic alterations (AC versus placebo), Outcome 3 Thoracic semeiologic alterations after 5 days.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Thoracic semeiologic alterations (AC versus placebo), Outcome 4 Thoracic semeiologic alterations at the end of treatment (= 28 days).
[Analysis 4.5]
Analysis 4.5. Comparison 4 Thoracic semeiologic alterations (AC versus placebo), Outcome 5 Thoracic semeiologic alterations at the end of treatment (= 28 days).
[Analysis 5.1]
Analysis 5.1. Comparison 5 General condition (CC versus placebo), Outcome 1 Bad general condition after 6 to 7 days.
[Analysis 5.2]
Analysis 5.2. Comparison 5 General condition (CC versus placebo), Outcome 2 Bad general condition after 6 to 7 days.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Cough productivity (AC versus placebo), Outcome 1 Cough productivity at the end of treatment (= 28 days).
[Analysis 6.2]
Analysis 6.2. Comparison 6 Cough productivity (AC versus placebo), Outcome 2 Cough productivity at the end of treatment (= 28 days).
[Analysis 7.1]
Analysis 7.1. Comparison 7 Appetite (CC versus placebo), Outcome 1 Appetite trouble at the end of treatment (5 to 9 days).
[Analysis 8.1]
Analysis 8.1. Comparison 8 Expectoration (CC versus placebo), Outcome 1 Expectoration at the end of treatment (= 7 days).
[Analysis 8.2]
Analysis 8.2. Comparison 8 Expectoration (CC versus placebo), Outcome 2 Expectoration at the end of treatment (= 7 days).
[Analysis 9.1]
Analysis 9.1. Comparison 9 Pulmonary function tests (CC versus placebo), Outcome 1 Alteration of the pulmonary function after 3 days.
[Analysis 9.2]
Analysis 9.2. Comparison 9 Pulmonary function tests (CC versus placebo), Outcome 2 Alteration of the pulmonary function after 3 days.